Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

NCT00799435 · Terminated

Last updated 2026-05-28

This clinical trial is testing whether the medication exenatide can help reduce stiffness in the aorta in adults with both type 2 diabetes and diastolic heart failure.

Status Terminated Stopped early and will not restart.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 2 people

Who can join Ages 30+ · all sexes

Timeline Started 2009-07 · est. completion 2012-04

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00799435 ↗

Description as written by the study sponsor.

People with type 2 diabetes experience heart failure more often than do people without diabetes. This may be due to increased stiffness in the heart as a result of diabetes. This study will examine whether exenatide, a medication used to treat diabetes, may have beneficial effects on the heart in people with type 2 diabetes and heart failure.

Treatments tested

Exenatide also known as Byetta Drug

5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks

Main thing measured	Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity
Sponsor	Baylor College of Medicine
Conditions studied	Diabetes Mellitus, Type 2, Heart Failure, Diastolic
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00799435 ↗